Citations

Showing 10 of 108104 citations.

2289. Accuracy of a Rapid Multiplex PCR Plus a Chromogenic Phenotypic Test Algorithm for the Detection of ESBL and Carbapenemase-Producing Gram Negatives Directly From Blood Cultures
Hon, Pei-Yun, Wee, Sharon , Chia, Jonathan W. Z., Mendis, Shehara M, Izharrudin, Ezlyn, Lin, Ray J H, Chia, Po Ying , Sim, Rees Chin Swee, Teng, Christine B. , Banerjee, Ritu , De, Partha Pratim, Vasoo, Shawn , Lin, Ray J H, Chen, Mark , Chow, Angela , Yoong, Joanne , Lye, David Chien , Tambyah, Paul Anantharajah , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S678-S678

10.1093/ofid/ofy210.1942 Get It

1085. Enterococcal Cardiac Implantable Electronic Device (CIED) Infections: Clinical Features and Outcomes
Oh, Timothy S. , Peacock, James E. , Le, Katherine, Prutkin, Jordan M. , Greenspon, Arnold J. , Danik, Stephan B., Naber, Christoph, Blank, Elisabeth, Tseng, Chi‐Hong , Sohail, M. Rizwan , Baddour, Larry M. , Vikram, Holenarasipur R. , Miró, José María , Carrillo, Roger G. , Uslan, Daniel Z.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S325-S325

10.1093/ofid/ofy210.920 Get It

Abstract Background Unlike enterococcal native and prosthetic valve infective endocarditis (IE), enterococcal CIED infections are not well described. Methods Data from the Multicenter Electrophysiologic Device Infection Collaboration (MEDIC), a prospective, observational, multinational cohort study of CIED infections, were used to provide a descriptive analysis of adult patients with CIED infections due to enterococcal species. Results Of 433 patients, 21 (4.8%) were diagnosed with enterococcal CIED infection. Specific data on enterococcal species and antimicrobial susceptibilities were not recorded. The mean age was 70.8 years. No patient had previous CIED infection. Twelve patients (57%) had permanent pacemakers, 5 (24%) had implantable cardioverter defibrillators, and 4 (19%) had biventricular devices. Among the 21 infections, 3 (14%) were categorized as CIED-related bloodstream infections and 18 (86%) as IE; no patient had isolated pocket infection. Of the IE cases, four were valvular IE, eight were lead IE, and six were both. Fourteen cases of IE (78%) were definite by the modified Duke criteria. Median time from last device procedure to infection was 510 days (range 37–2,952 days). The most common presenting symptom was fever (48%); five patients (24%) exhibited local signs of pocket infection. All 21 patients underwent TEE with vegetations demonstrated in 17 (81%). Blood cultures grew enterococci from all patients. The most common antimicrobial regimen was a penicillin plus aminoglycoside (38%); two patients (9.5%) received ampicillin + ceftriaxone. Antibiotics were given for a median of 43 days. Only 14 patients (67%) had complete device removal; the seven patients retaining their device were judged to be at high risk for extraction. There was one death during the index hospital stay with four additional patients dying over the 6 months after therapy (overall mortality 24%); two of the seven patients retaining their CIED died. Conclusion Enterococci caused 4.8% of all CIED infections in our cohort. Most infections appeared to be hematogenous in origin with late onset. IE was the most common infectious syndrome. A penicillin plus aminoglycoside, given for 6 weeks, was the most frequent therapy. Only 67% of patients underwent device removal. At 6 months follow-up, no relapses had occurred but overall mortality was 24%. Disclosures J. E. Peacock Jr., Pfizer, Inc.: Shareholder, Owns common stock in Pfizer which was inherited and held in a trust. M. R. Sohail, TyRx Inc.: Investigator, Research support. Medtronic Inc.: Investigator, Research support. Medtronic Inc.: Consultant, Speaker honorarium. Spectranetics: Consultant, Speaker honorarium. Boston Scientific Corp: Consultant, Speaker honorarium. L. M. Baddour, UpToDate: Collaborator, Royalty payment. J. M. Miro, Abbvie: Consultant and Grant Investigator, Consulting honoraria and Research grant. Bristol-Myers Squibb: Consultant and Grant Investigator, Consulting honoraria and Research grant. Genentech: Consultant and Grant Investigator, Consulting honoraria and Research grant. Medtronic: Consultant and Grant Investigator, Consulting honoraria and Research grant. Novartis: Consultant and Grant Investigator, Consulting honoraria and Research grant. Gilead Sciences: Consultant and Grant Investigator, Consulting honoraria and Research grant. Pfizer: Consultant and Grant Investigator, Consulting honoraria and Research grant. ViiV Healthcare: Consultant and Grant Investigator, Consulting honoraria and Research grant. A. J. Greenspon, Medtronic: Consultant, Speaker honorarium. Boston Scientific: Consultant, Speaker honorarium. St. Jude: Consultant, Speaker honorarium. R. G. Carrillo, St. Jude Medical Group: Speaker’s Bureau, Research support. Spectranetics: Consultant, Speaker honorarium. Sorin Group: Speaker’s Bureau, None. Boston Scientific Corp: Speaker’s Bureau, None. D. Z. Uslan, Medtronic: Investigator, Research support. Boston Scientific: Consultant, Speaker honorarium.
2029. Comparison of Primers Amplifying Two Different Regions of the 16S Ribosomal RNA Gene for Microbiologic Diagnosis of Cardiovascular Implantable Electronic Device Infection
Garrigos, Zerelda Esquer , Greenwood‐Quaintance, Kerryl E. , Vijayvargiya, Prakhar , Thoendel, Matthew , Friedman, Paul A. , Sohail, M. Rizwan , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S591-S591

10.1093/ofid/ofy210.1685 Get It

250. Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study
Shah, Aditya , Dhungana, Prabij, Sampathkumar, Priya , Bohman, J. Kyle , O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S106-S106

10.1093/ofid/ofy210.261 Get It

2035. Detection of Blastomyces dermatitidis Antigen in Urine Using a Novel Quantitative Enzyme-linked Immunosorbent Assay
Granger, Dane

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S593-S593

10.1093/ofid/ofy210.1691 Get It

1042. Stenotrophomans maltophilia Bacteremia, A 10-Year Tertiary Center Experience
Hamdi, Ahmed , AbuSaleh, Omar, Fida, Madiha , Beam, Elena

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S311-S311

10.1093/ofid/ofy210.879 Get It

Abstract Background Stenotrophomonas maltophilia is a hospital acquired infection that is associated with high morbidity and mortality. There has been a reported rise in S. maltophilia infections, presumed secondary to the increase in the population at risk. Methods We retrospectively reviewed all hospitalized adult patients in Mayo Clinic, MN with S. maltophilia bacteremia from January 2008 through January 2018. We analyzed patient population and described patients at risk, sources of infection, and changes in antimicrobial susceptibility profile. Results A total of 94 patients were analyzed, including 52 males, median age of 56 (46–65.75 IQR). The population included 60 infections in those with malignancies and 30 infections in transplant recipients. At presentation, 58 (61.7%) were febrile, while 54 (58.1%) presented with hemodynamic instability. Majority (70.2%) received broad-spectrum antimicrobials within 2 weeks of presentation. The most common source was catheter associated infection (n = 60), 15 cases were secondary to gastrointestinal, and 9 due to a pulmonary source. Almost half, 46 (48.9%) required ICU admission. Two patients were diagnosed with endocarditis. Most isolates, 61(64.9%), were resistant to ceftazidime, 2 (2.2%) resistant to TMP/SMX and 20 (21.5%) were resistant to levofloxacin. Exposure to a quinolone in the 30 days prior to presentation did not impact fluoroquinolone resistance. Five patients were exposed to Trimethoprim/Sulfamethoxazole (TMP/SMX) in the 30 days prior to presentation, which was associated with higher rate of TMP/SMX resistance compared with those without exposure (80% vs. 98.8%, P = 0.004). Treatment options commonly included combination therapy, and TMP/SMX was a primary agent used in the majority, 59 (62.8%). All-cause in-hospital mortality was 26.6%. All-cause mortality was lower for line associated infections (16.67%) vs. other sources (44.12%) with P = 0.0038. Conclusion S. maltophilia bacteremia should be considered in hospitalized patients with recent use of broad-spectrum antibiotics. Although TMP/SMX continues to have reliable activity, use of empiric ceftazidime pending susceptibility testing should be avoided as trend toward increasing resistance is noted. We noted a drop in TMP/SMX susceptibility in those with recent reported TMP/SMX use. Disclosures All authors: No reported disclosures.
1637. Improving Transitions of Care in the Division of Infectious Diseases
Paim, Ana C. , Vijayvargiya, Prakhar , Garrigos, Zerelda Esquer , Tan, Eugene M. , O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S44-S45

10.1093/ofid/ofy209.107 Get It

Abstract Background Patients dismissed from the hospital on oral or intravenous antibiotics frequently need follow-up appointments with the Division of Infectious Diseases (ID). Follow-up appointments may be inappropriately scheduled with respect to timing and indication. Suboptimal transitions of care may lead to increased no-shows and ultimately poor patient outcomes. Methods The baseline sample included 102 patients seen by the inpatient ID services at Mayo Clinic’s Rochester Methodist and Saint Mary’s Hospitals between January 1, 2017 and June 30, 2017. Defects in transitions of care were categorized as those pertaining to sign-off templates, sign-off labels, follow-up priority, and timing. The current transfer of care system from our institution is outlined in Figure 1. Results Out of 102 patients, 75 (74%) had at least one defect identified. Root cause analysis revealed multiple factors contributing to this performance gap (Figure 2). Patients often have variable health literacy and social or financial difficulties. There are often multiple ID providers with inadequate time to properly orchestrate follow-up. There are undefined checkpoints and triaging in the department’s scheduling policies. Interventions involved reformatting the ID sign-off template and clarifying the roles of providers in the transitions-of-care process. Analysis after 6 months of implementation revealed improvement of communication among teams, decline in improper sign off by 13% and decrease in antibiotic prescription errors by 2%. Conclusion This study demonstrates that well-designed sign-off templates can help with effective communication of the final treatment plan among providers and possibly improve patient outcomes. The target goal is to reduce the number of improper sign-offs by 50% within 1 year. Disclosures All authors: No reported disclosures.
1074. Management and Outcomes of Infective Endocarditis Due to Nutritionally Variant Streptococci
Mansoor, Tarab, Saleh, Omar Abu , Hamdi, Ahmed , Wilson, Walter R. , Steckelberg, James M., Fida, Madiha , DeSimone, Daniel C. , Baddour, Larry M. , Sohail, M. Rizwan

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S321-S322

10.1093/ofid/ofy210.911 Get It

Abstract Background Nutritionally variant streptococci (NVS) are an infrequent cause of infective endocarditis (IE) and management recommendations are based on weak levels of evidence largely derived from case reports, small case series, and animal models of experimental endocarditis. Moreover, taxonomic changes have led to some confusion in designation of these organisms. Methods We retrospectively collected and analyzed data from 33 patients with NVS IE from 1970 to 2017. Only patients who met modified Duke Criteria for IE were included. Results Mean patient age was 55 years and 61% were males. The most common comorbidities included diabetes mellitus (12%), malignancy (3%), heart failure (16%), coronary artery disease (25%), and chronic liver disease (9%). Predisposing valve abnormalities included rheumatic heart disease (11%), bicuspid aortic valve (22%), transplant valvulopathy (3%), mitral valve prolapse (3%), and congenital heart disease (11%). Cultures were reported as NVS (70%), Granulicatella species (18%) and Abiotrophia species (12%). Echocardiogram findings included vegetations (67%), new regurgitation (55%), perivalvular abscess (3%), mitral valve prolapse (3%), and ruptured mitral valve chordae (3%). Both prosthetic (26%) and native valve IE (74%) was seen, and the valves involved were aortic (37%), mitral (50%) and both aortic and mitral (13%). Complications were seen in 27% of patients, including heart failure (17%), splenic infarct (11%), stroke (8%), mycotic aneurysm (3%), and glomerulonephritis (2%). In vitro susceptibility to penicillin, ceftriaxone, and vancomycin was 88%, 80%, and 100%, respectively. The majority (77%) of patients were treated with a combination of β-lactam and aminoglycoside. Median duration of treatment was 33 days. Surgery was performed in 50% of patients with no significant difference in survival between those who were treated with combined medical/surgical treatment and those treated with medical therapy alone. Overall survival at 1, 4, and 10 years was 93%, 83%, and 66%, respectively. Conclusion IE due to NVS is a rare entity and is associated with a high rate of serious complications and may involve multiple valves. Long-term, two-thirds of the patients survived more than 10 years. Disclosures All authors: No reported disclosures.
439. Impact of Pre-Travel Consultation on Clinical Management and Outcomes of Traveler’s Diarrhea
Tan, Eugene M. , Sauver, Jennifer L. St. , Sia, Irene G.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S165-S165

10.1093/ofid/ofy210.449 Get It

2169. Map the Gap: A Novel Approach Using Big Data to Determine the State of the Infectious Diseases Workforce and Fecal Transplant Centers with Regards to Clostridium Difficile Infection
Shah, Aditya , Stone, Eric C., O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S640-S640

10.1093/ofid/ofy210.1825 Get It